Marie Bosslett, Assistant Editor

Chronic skin diseases like psoriasis and AD are linked to high smoking and other addiction rates, highlighting the need for integrated psychosocial support.

Elderly populations are facing rising cutaneous malignant melanoma incidence and mortality, highlighting urgent needs for targeted prevention and early detection strategies in skin cancer care.

Explore the latest findings on GLP-1 RA injection-site and dermatologic reactions, enhancing treatment adherence and patient counseling strategies.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Discover essential dermatology awareness dates and initiatives for 2026, as we enhance patient care with updates, interviews, and resources throughout the year.

Explore top dermatology conferences and meetings in January 2026 and let us know which ones you'll be attending!

Share your thoughts and help shape our content by telling us what topics you want to see more of this year.

Discover the top dermatology conferences and meetings for 2026, and share your insights on upcoming events in the field.

Innovative approaches in 2025 have enhanced skin health equity by improving global access to dermatology trials, ensuring diverse representation, and community engagement.

Explore key insights and highlights from the major dermatology conferences Dermatology Times attended in 2025, featuring expert speakers and innovative clinical practice tips.

Aesthetic dermatology in 2025 emphasizes innovation, safety, and natural results, reshaping patient care with personalized treatment plans and advanced technologies.

Discover the 2025 advancements in AD treatment, including new therapies, pediatric approvals, and insights into effective management strategies.

CHE has gained attention in 2025 with an FDA-approved treatment and new insights, addressing its significant impact on patients' lives and work.

As 2025 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in rosacea this year.

The Society of Dermatology Physician Assistants (SDPA) 23rd Annual Fall Dermatology Conference highlights mentorship, leadership, and innovative education, shaping the future of dermatology and enhancing patient care.

As 2025 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in acne this year.

Read on to catch up on all of the episodes of Derm Dispatch from this year.

Spizuoco leads the inaugural DermVIP Summit, enhancing alopecia education for dermatology professionals through expert insights and innovative treatments.

Brad Glick, DO, MPH, and attendees discuss innovative treatments for atopic dermatitis, emphasizing the importance of patient comfort and modern nonsteroidal options.

Discover how NPs and PAs shaped the future of dermatology this year as leaders inspire the next generation to thrive in their careers.

Find out what skin care products and aesthetic innovations clinicians have recommended to patients in 2025.

Explore our top performing social media posts of 2025, including insights on the latest clinical trials, FDA approvals, and more.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

In case you missed it, this week we had news on phase 3 data for zasocitinib in psoriasis, wildfire air pollution's impact on AD clinic visits, the FDA's clearance of REX-8756's IND application, and more.

Discover the latest trends in aesthetic dermatology for 2025, including innovative treatments and the impact of social media on patient choices.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of December.

Experts discuss real-world strategies for managing alopecia areata, emphasizing JAK inhibitors, psychosocial impacts, and personalized patient care approaches.

What were the top dermatology hits of 2025?

A study reveals stress coping strategies and eosinophil levels impact CU in adolescents, highlighting the need for integrated psychological support.

Soligenix reveals promising results from its phase 2a study of SGX302, a novel therapy for mild-to-moderate psoriasis, enhancing patient experience and efficacy.